Dr. Reddy's Laboratories received one of its most anticipated regulatory wins in years on Tuesday — Health Canada approved its generic semaglutide injection, making it the first generic version of Novo Nordisk's blockbuster Ozempic to clear a major market regulator. The stock still fell 2.1% on the day. That tension — material catalyst, negative price reaction — sets up the most interesting question heading into next week's earnings.
The week's overall picture is more positive. RDY climbed nearly 7% over the five sessions to $13.73. Short sellers treated the rally as an exit. Estimated short interest dropped 9.6% over the week to roughly 13.9 million shares — the lowest level in over a month — as bearish positions unwound into strength. Borrow conditions reinforce how low-conviction that short book is: cost to borrow runs at just 0.56%, and availability is comfortable. There is no squeeze pressure here. The semaglutide catalyst brought in buyers, then triggered a round of profit-taking on the approval day itself.
Options positioning tells a broadly constructive story, though without the conviction you might expect after a landmark approval. The put/call ratio of 0.066 is slightly below its 20-day average of 0.075 — call volume is running a touch heavier than put volume, but the gap is modest and the z-score barely registers at -0.84. Given that the 52-week range runs from 0.009 all the way to 1.83, current positioning is neither aggressively bullish nor defensively hedged. Traders appear to be waiting rather than betting.
The Street's view on RDY's US-listed ADR is difficult to read with precision — most analyst coverage runs against the Indian-listed shares, where targets are quoted in rupees. The most recent USD-referenced action came from HSBC, which upgraded to Buy with a $16.90 target back in June 2025, and Barclays, which held Overweight with a $17.00 target in November 2024. Both are stale but point in the same direction: the consensus leans positive, with the stock trading at a discount to where the most recent bullish calls were made. The current PE multiple of 23.9x and EV/EBITDA of 13.9x are not demanding for a generics player with a live semaglutide franchise. The dividend score ranks in the 91st percentile across the universe — a signal of capital return consistency, even if the last declared dividend dates back to 2022 in the available data.
Institutional flows add quiet support. Boston Partners added over 4 million shares in the most recent quarter, making it the most aggressive buyer among the top fifteen holders in that period. JPMorgan Asset Management and PPFAS Asset Management both added meaningfully. The founding families — Kallam Reddy and Gunupati Prasad, together holding over 26% — trimmed fractionally, well within normal housekeeping range. There is no evidence of insider conviction selling; the most recent insider sale on record was a small employee disposal in July 2025.
The next focal point is the Q4 earnings call on May 8. The last four earnings events produced only modest daily moves — the biggest was a 2% gain in February 2026 — suggesting the stock does not historically whipsaw dramatically around results. The more consequential question now is how management frames the commercial timeline for generic semaglutide in Canada, and whether any US filing update is included. The approval is real; what the market is still pricing is how fast the revenue follows.
See the live data behind this article on ORTEX.
Open RDY on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
